Health on MSN

What causes complement 3 glomerulopathy, a rare kidney condition?

Medically reviewed by David Ozeri, MD Complement 3 glomerulopathy (C3G) is a rare kidney disorder—in many cases, the exact cause is unknown.Possible C3G causes include genetic mutations, ...
Geeky Gadgets

Build Faster Excel Workflows Using FILTER, IFS, XLOOKUP, and LET for Real-World Data

What if you could transform hours of tedious spreadsheet work into just minutes of streamlined efficiency? Simon Sez IT takes a closer look at how Excel’s most powerful functions can transform the way ...
Hosted on MSN

Activation functions in neural networks: Types and examples

In this video, we will see What is Activation Function in Neural network, types of Activation function in Neural Network, why to use an Activation Function and which Activation function to use. The ...
BioSpace

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...
Investing

Omeros stock soars after FDA approves first treatment for TA-TMA

Investing.com -- Omeros Corporation (NASDAQ:OMER) stock surged 61.6% Wednesday after the FDA approved YARTEMLEA, the first and only treatment for hematopoietic stem cell transplant-associated ...
Nasdaq

Omeros Wins FDA Approval For YARTEMLEA In Transplant-Associated Thrombotic Microangiopathy

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...
MarketWatch

Omeros Gets FDA Approval of Yartemlea

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...